
Daily Derm Times: August 5, 2025
Key Takeaways
- Clinicians are examining diverse AD cases to integrate newer agents into evolving treatment strategies.
- Immutep is advancing eftilagimod alfa for HNSCC patients with low PD-L1 expression and limited treatment options.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our
Real Cases Drive Honest Dialogue on Topicals for AD
Temitayo Ogunleye, MD, guided clinicians through diverse AD cases to examine how newer agents fit into evolving treatment strategies.
Immutep Gains FDA Support for Eftilagimod Alfa Development in HNSCC Patients with Low PD-L1 Expression
Immutep advances eftilagimod alfa for head and neck squamous cell carcinoma, targeting patients with low PD-L1 expression and limited treatment options.
Inadequate Relief for Patients with CSU Is Driving a Search for Alternatives Around the World
According to a new poster, patients with chronic spontaneous urticaria seek better relief options, highlighting significant impacts on quality of life and mental well-being globally.
Sybert Stresses Smart Genetic Testing in Dermatology
Virginia Sybert, MD, emphasized the importance of using genetic testing judiciously in dermatologic care.
Elevate-Derm Summer 2025: Full Conference Recap
Unlock exclusive insights from Elevate-Derm Summer 2025 and get expert pearls, emerging data, and clinical strategies at your fingertips.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















